A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
Cardiopulmonary resuscitation and defibrillation are the only effective therapeutic options during cardiac arrest caused by ventricular fibrillation. This model presents a standardized regimen to induce, assess, and treat this physiological state in a porcine model, thus providing a clinical approach with various opportunities for data collection and analysis.
Cardiopulmonary resuscitation after cardiac arrest, independent of its origin, is a regularly encountered medical emergency in hospitals as well as preclinical settings. Prospective randomized trials in human subjects are difficult to design and ethically ambiguous, which results in a lack of evidence-based therapies. The model presented in this report represents one of the most common causes of cardiac arrests, ventricular fibrillation, in a standardized setting in a large animal model. This allows for reproducible observations and various therapeutic interventions under clinically accurate conditions, hence facilitating the generation of better evidence and eventually the potential for improved medical treatment.
Cardiac arrest and cardiopulmonary resuscitation (CPR) are regularly encountered medical emergencies in hospital wards as well as preclinical emergency provider scenarios1,2. While there have been extensive efforts to characterize the optimal treatment for this situation3,4,5,6, international guidelines and expert recommendations (e.g., ERC and ILCOR) usually rely on low-grade evidence due to the lack of prospective randomized trials3,4,5,7,8,9. This is in part due to obvious ethical reservations regarding randomized resuscitation protocols in human trials10. However, this may also point towards a lack of strict protocol adherence when confronted with a life-threatening and stressful situation11,12. The protocol presented in this report aims to provide a standardized resuscitation model in a realistic clinical setting, which generates valuable, prospective data while being as valid and accurate as possible without the need for human subjects. It adheres to common resuscitation guidelines, can be easily applied, and enables researches to examine and characterize various aspects and interventions in a critical but controlled setting. This will lead to 1) a better understanding of the pathological mechanisms underlying cardiac arrest and ventricular fibrillation and 2) higher quality evidence in order to optimize treatment options and increase survival rates.
The experiments in this protocol were approved by the State and Institutional Animal Care Committee (Landesuntersuchungsamt Rheinland-Pfalz, Koblenz, Germany; Chairperson: Dr. Silvia Eisch-Wolf; approval no. G16-1-042). The experiments were conducted in accordance with the ARRIVE guidelines. Seven anesthetized male pigs (sus scrofa domestica) with a mean weight of 30 ± 2 kg and 12-16 weeks in age were included in the protocol.
1. Anesthesia, intubation, and mechanical ventilation13,14
2. Instrumentation
3. Pulse contour cardiac output
4. Ventricular fibrillation and mechanical resuscitation
5. End of experiment and euthanasia (in the case of ROSC)
Cardiac arrest was induced in seven pigs. Return of spontaneous circulation following CPR was achieved in four Pigs (57%) with a mean of 3 ± 1 biphasic defibrillations. Healthy and adequately anesthetized pigs should stay in supine position without shivering and signs of agitation throughout the entire experiment. Mean arterial blood pressures should not drop below 50 mmHg before initiation of fibrillation18. For optimal results, blood gas analyses can be perf...
Some major technical issues regarding anesthesia in a porcine model have previously been described by our group13,14. These include the strict avoidance of stress and unnecessary pain for the animals, possible anatomical problems during airway management, and specific personnel requirements19.
Additionally, the benefits of ultrasound-guided catheterization was highlighted previously and remains the preferable ap...
The LUCAS-2 device was provided unconditionally by Stryker/Physio-Control, Redmond, WA, USA for experimental research purposes. No authors report any conflicts of interest.
The authors want to thank Dagmar Dirvonskis for excellent technical support.
Name | Company | Catalog Number | Comments |
1 M- Kaliumchlorid-Lösung 7,46% 20ml | Fresenius, Kabi Deutschland GmbH | potassium chloride | |
Arterenol 1mg/ml 25 ml | Sanofi- Aventis, Seutschland GmbH | norepinephrine | |
Atracurium Hikma 50mg/5ml | Hikma Pharma GmbH, Martinsried | atracurium | |
BD Discardit II Spritze 2,5,10,20 ml | Becton Dickinson S.A. Carretera Mequinenza Fraga, Spain | syringe | |
BD Luer Connecta | Becton Dickinson Infusion Therapy AB Helsingborg, Schweden | 3-way-stopcock | |
BD Microlance 3 20 G | Becton Dickinson S.A. Carretera Mequinenza Fraga, Spain | canula | |
CorPatch Easy Electrodes | CorPuls, Kaufering, Germany | defibrillator electrodes | |
Corpuls 3 | Corpuls, Kaufering, Germany | defibrillator | |
Datex Ohmeda S5 | GE Healthcare Finland Oy, Helsinki, Finland | hemodynamic monitor | |
Engström Carestation | GE Heathcare, Madison USA | ventilator | |
Fentanyl-Janssen 0,05mg/ml | Janssen-Cilag GmbH, Neuss | fentanyl | |
Führungsstab, Durchmesser 4.3 | Rüsch | endotracheal tube introducer | |
Incetomat-line 150 cm | Fresenius, Kabi Deutschland GmbH | perfusorline | |
Ketamin-Hameln 50mg/ml | Hameln Pharmaceuticals GmbH | ketamine | |
laryngoscope | Rüsch | laryngoscope | |
logicath 7 Fr 3-lumen 30cm lang | Smith- Medical Deutschland GmbH | central venous catheter | |
LUCAS-2 | Physio-Control/Stryker, Redmond, WA, USA | chest compression device | |
Masimo Radical 7 | Masimo Corporation Irvine, Ca 92618 USA | periphereal oxygen saturation | |
Neofox Oxygen sensor 300 micron fiber | Ocean optics Largo, FL USA | ultrafast pO2-measurements | |
Ölsäure reinst Ph. Eur NF C18H34O2 M0282,47g/mol Dichte 0,9 | Applichem GmbH Darmstadt, Deutschland | oleic acid | |
Original Perfusor syringe 50ml Luer Lock | B.Braun Melsungen AG, Germany | perfusorsyringe | |
Osypka pace, 110 cm | Osypka Medical GmbH, Rheinfelden-Herten, Germany | Pacing/fibrillation catheter | |
PA-Katheter Swan Ganz 7,5 Fr 110cm | Edwards Lifesciences LLC, Irvine CA, USA | PAC | |
Percutaneous sheath introducer set 8,5 und 9 Fr, 10 cm with integral haemostasis valve/sideport | Arrow international inc. Reading, PA, USA | introducer sheath | |
Perfusor FM Braun | B.Braun Melsungen AG, Germany | syringe pump | |
Propofol 2% 20mg/ml (50ml flasks) | Fresenius, Kabi Deutschland GmbH | propofol | |
Radifocus Introducer II, 5-8 Fr | Terumo Corporation Tokio, Japan | introducer sheath | |
Rüschelit Super Safety Clear >ID 6/ 6,5 /7,0 mm | Teleflex Medical Sdn. Bhd, Malaysia | endotracheal tube | |
Seldinger Nadel mit Fixierflügel | Smith- Medical Deutschland GmbH | seldinger canula | |
Sonosite Micromaxx Ultrasoundsystem | Sonosite Bothell, WA, USA | ultrasound | |
Stainless Macintosh Größe 4 | Welsch Allyn69604 | blade for laryngoscope | |
Stresnil 40mg/ml | Lilly Deutschland GmbH, Abteilung Elanco Animal Health | azaperone | |
Vasofix Safety 22G-16G | B.Braun Melsungen AG, Germany | venous catheter | |
Voltcraft Model 8202 | Voltcraft, Hirschau, Germany | oscilloscope/function generator |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved